Fenfluramine low dose - Zogenix

Drug Profile

Fenfluramine low dose - Zogenix

Alternative Names: Brabafen; Fintepla; Low-dose fenfluramine; ZX-008

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brabant Pharma
  • Developer Brabant Pharma; Zogenix
  • Class Amphetamines; Anorectics; Antiepileptic drugs; Small molecules
  • Mechanism of Action Serotonin receptor agonists; Sigma-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome
  • New Molecular Entity No

Highest Development Phases

  • Phase III Dravet syndrome; Lennox-Gastaut syndrome
  • Preclinical Epilepsy

Most Recent Events

  • 04 Dec 2017 Additional efficacy and adverse events data from two phase III trials in Dravet Syndrome released by Zogenix
  • 29 Nov 2017 Phase-III clinical trials in Lennox-Gastaut syndrome (In children, In adolescents, In adults, Adjunctive treatment) in USA (PO) (NCT03355209)
  • 29 Sep 2017 Zogenix announces intention to submit regulatory applications in USA and Europe Dravet syndrome in second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top